Kohlberg Kravis Roberts & Co’s BridgeBio Pharma BBIO Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$985M	Hold	13,260,971	–	–	18.42%	3
2025 Q4	$1.01B	Hold	13,260,971	–	–	16.22%	3
2025 Q3	$689M	Hold	13,260,971	–	–	11.54%	3
2025 Q2	$573M	Sell	13,260,971 -6,000,000	-31%	-$218M	11.83%	3
2025 Q1	$666M	Sell	19,260,971 -6,000,000	-24%	-$202M	15.04%	3
2024 Q4	$693M	Hold	25,260,971	–	–	18.56%	2
2024 Q3	$643M	Sell	25,260,971 -5,800,000	-19%	-$152M	8.61%	3
2024 Q2	$787M	Hold	31,060,971	–	–	23.6%	2
2024 Q1	$960M	Hold	31,060,971	–	–	24.77%	1
2023 Q4	$1.25B	Hold	31,060,971	–	–	37.06%	1
2023 Q3	$819M	Hold	31,060,971	–	–	28.75%	1
2023 Q2	$534M	Hold	31,060,971	–	–	16.54%	2
2023 Q1	$515M	Hold	31,060,971	–	–	15.5%	2
2022 Q4	$237M	Hold	31,060,971	–	–	7.99%	4
2022 Q3	$309M	Hold	31,060,971	–	–	6.2%	6
2022 Q2	$282M	Hold	31,060,971	–	–	3.75%	6
2022 Q1	$315M	Hold	31,060,971	–	–	2.86%	7
2021 Q4	$518M	Hold	31,060,971	–	–	2.84%	6
2021 Q3	$1.46B	Hold	31,060,971	–	–	7.26%	3
2021 Q2	$1.89B	Hold	31,060,971	–	–	7.68%	3
2021 Q1	$1.91B	Sell	31,060,971 -3,450,000	-10%	-$226M	9.64%	3
2020 Q4	$2.45B	Hold	34,510,971	–	–	12.45%	2
2020 Q3	$1.29B	Hold	34,510,971	–	–	7.4%	3
2020 Q2	$1.13B	Sell	34,510,971 -2,389,690	-6%	-$72.8M	6.87%	3
2020 Q1	$1.07B	Hold	36,900,661	–	–	6.83%	3
2019 Q4	$1.29B	Hold	36,900,661	–	–	6.32%	3
2019 Q3	$792M	Hold	36,900,661	–	–	4.46%	4
2019 Q2	$995M	Buy	+36,900,661	New	+$1.01B	12.26%	3

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's BBIO Position: Q1 2026 in Review

Kohlberg Kravis Roberts & Co held its BridgeBio Pharma (BBIO) position steady in Q1 2026 at 13,260,971 shares worth $985M. The position accounts for 18.42% of the portfolio, ranked #3.

Kohlberg Kravis Roberts & Co first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. The position peaked at $2.45B in Q4 2020. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Kohlberg Kravis Roberts & Co held 13,260,971 shares of BridgeBio Pharma worth $985M as of Q1 2026.
Kohlberg Kravis Roberts & Co left its BridgeBio Pharma share count unchanged in Q1 2026.
BridgeBio Pharma made up 18.42% of Kohlberg Kravis Roberts & Co's portfolio in Q1 2026, its #3 holding.
Kohlberg Kravis Roberts & Co first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
Kohlberg Kravis Roberts & Co's BridgeBio Pharma position peaked at $2.45B in Q4 2020.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q1 2026, filed 15 May 2026.